<DOC>
	<DOCNO>NCT00034203</DOCNO>
	<brief_summary>The purpose study determine whether humanized monoclonal antibody ( efalizumab ) safe effective treatment rheumatoid arthritis .</brief_summary>
	<brief_title>Safety Efficacy Monoclonal Antibody Treatment Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis moderate severe rheumatoid arthritis . On stable dose methotrexate . 18 80 year age . Less 275 lb . Exclusion criterion : Joint replacement surgery within 60 day start drug dosing . Intraarticular cortisone injection within 28 day start drug dosing . Pregnancy . History severe allergic anaphylactic reaction . Active bacterial , viral , fungal , mycobacterium tuberculosis . Positive PPD test . History opportunistic infection . Serious persist local systemic infection . History malignancy within past five year . Received vaccine within 28 day start study drug dose . Joint replacement therapy plan within nine month start study drug dose . Chronic disorder apart RA affect joint . Significant systemic involvement secondary RA . COPD , asthma , pulmonary disease . Received DMARD methotrexate 28 day prior start study drug dosing . Approved biologic RA therapy 28 day 7 halflives drug prior start drug dosing . Investigational drug and/or treatment 28 day seven halflives investigational drug prior start study drug dose . Liver disease abnormal hepatic function . Serum creatinine level &gt; 1.5 mg/dL . Platelet count &lt; 125,000 cells/mm3 . WBC count &lt; 3,500 cells/mm3 . Seropositive hepatitis B surface antigen . Seropositive hepatitis C antibody . Known seropositivity HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2004</verification_date>
</DOC>